Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes

@article{Jinnouchi2006AtorvastatinDS,
  title={Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes},
  author={Yoshiteru Jinnouchi and Sho-ichi Yamagishi and Masayoshi Takeuchi and Shimpei Ishida and Juro Jinnouchi and Takahiro Imaizumi},
  journal={Clinical and Experimental Medicine},
  year={2006},
  volume={6},
  pages={191-193}
}
Lipid-lowering agents, statins and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors have recently been shown to reduce the risk for cardiovascular events in diabetic patients [1]. Indeed, the Collaborative Atorvastatin Diabetes Study (CARDS), a multicentre randomised placebo-controlled trial, revealed that atorvastatin prevented first cardiovascular events including stroke in patients with type 2 diabetes without high low-density lipoprotein (LDL)-cholesterol levels [1]. Intensive… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-8 of 8 references

Similar Papers

Loading similar papers…